Mesoblast and FDA Align on Key Items for Revascor® Biologic License Application in Ischemic Heart Failure

Stock Information for Golden Star Resources Ltd

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Golden Star Resources Ltd

Successful Commercial Launch of Ryoncil® Highlighted at Global Healthcare Conferences
Mesoblast Enters Into Option To Issue US$50 Million Convertible Notes
Banner Year for Mesoblast With First FDA Product Approval and Successful Commercial Launch of Ryoncil®
Mesoblast Financial Results and Corporate Update Webcast
Successful Commercial Launch of Ryoncil®
Mesabi Trust Press Release
Mesoblast Maintains Momentum With FDA on Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure and Label Extension for Ryoncil® in Adults With GvHD
FDA Provides Seven Years of Orphan-Drug Exclusive Approval for Ryoncil®

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.